Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...

Men with metastatic castration-resistant prostate cancer (mCRPC) lived 19-20 months whether they received docetaxel plus pembrolizumab (Keytruda) or placebo. The addition of pembrolizumab did not ...

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...